Top Story Today
Gilead's Weekly HIV Pill Dream Just Hit a Dead End
Gilead pulled the plug on Wonders-2, its Phase 2/3 trial for a weekly oral HIV pill, after an FDA safety hold went unresolved. The problem: patients taking the two-drug combo saw drops in white blood cell counts, which is about the worst possible side effect for a virus that destroys the immune system. All 73 participants are being transitioned to standard treatments. Gilead's $20.8 billion HIV franchise isn't in danger (lenacapavir, its twice-yearly injection, just hit the market), but the company's pitch of "dosing optionality" just lost a key option.
Why it matters: Gilead dominates HIV with over 50% U.S. market share, and this setback narrows its strategy of offering patients every possible dosing format. With lenacapavir now carrying more weight than ever, the company's pipeline diversification story just got a lot thinner.
Read more →Clinical Wins and Losses
A Lung Drug Just Aced a Test It Was Never Built For
United Therapeutics' Tyvaso, already a $1.88 billion PAH drug, posted a 130.1 mL improvement in lung capacity over placebo in a Phase 3 IPF trial (p<0.0001). That's the strongest result ever seen in idiopathic pulmonary fibrosis, a disease with almost no effective treatments. Analysts project the IPF indication could add $1.5 billion in revenue by 2030. Shares jumped 12%.
Read more →Immunovant's Big Eye Disease Bet Just Went Blind
Immunovant's FcRn inhibitor batoclimab missed its primary endpoint in two Phase 3 trials for thyroid eye disease, sending shares down 8%. Combined with Argenx previously abandoning its own FcRn drug in TED, the failure raises a bigger question: maybe this entire drug class just doesn't work for this particular disease. Immunovant is pivoting to a next-gen molecule, IMVT-1402, with Graves' disease data expected in 2027.
Read more →Alto Neuroscience's Brain Patch for Schizophrenia Didn't Stick
Alto's PDE4 inhibitor ALTO-101, delivered via a transdermal patch, missed both primary endpoints in a Phase 2 schizophrenia trial. One key brain activity measure landed at p=0.052, a statistical photo finish that still counts as a loss. The company is shelving the program and redirecting resources toward treatment-resistant depression.
Read more →Deals and Funding
Merck Just Bet $838 Million on a Startup That Reads Your Immune System
Infinimmune, which raised approximately $22 million before this deal, landed an $838 million deal with Merck. The startup mines antibodies directly from human immune cells using AI, then optimizes them for drug development. For Merck, it's another hedge against the looming Keytruda patent cliff and part of a broader antibody shopping spree across the industry.
Read more →Another $100M Bet That You'll Ditch the Needle for a Pill
Ambrosia Biosciences closed a $100 million Series B for an oral small-molecule GLP-1 pill that hasn't been tested in a single human. The round, co-led by Blue Owl, Redmile, and Deep Track Capital, will fund a first-in-human trial for AMB-234. The obesity market is projected to hit $100 billion, and investors are betting the pill will eventually beat the needle.
Read more →A $6M Biotech Shell Just Became a $380M Alzheimer's Play Overnight
Korsana Biosciences is merging with near-empty Cyclerion Therapeutics to backdoor onto the Nasdaq, pairing the reverse merger with a $380 million PIPE. Korsana's preclinical Alzheimer's antibody uses shuttle technology to cross the blood-brain barrier. Cyclerion's stock surged over 300%, though shareholders only retain 1.5% of the combined entity.
Read more →Regulatory and Global Disruption
8,000 Clinical Trial Sites Just Went Dark in the Middle East
Nearly 8,000 trial sites across Turkey, Israel, and Egypt have been disrupted by the escalating Middle East conflict, affecting 4,361 active studies. Phase 3 oncology trials are hardest hit. Sea traffic through the Strait of Hormuz has dropped 90%, threatening drug supply chains. All ten of the world's largest pharma companies have exposure.
Read more →The FDA Just Put Orca Bio's Big Moment on Ice
The FDA delayed its decision on Orca-T, a precision cell therapy for blood cancers, by three months to July 2026. The reason: a manufacturing paperwork update classified as a "Major Amendment." No clinical concerns were raised. The delay adds Orca Bio to a growing list of companies caught in regulatory limbo as the FDA's on-time decision rate has slipped to 78%.
Read more →Science Spotlight
The Cancer Gene That Breaks Every Rule Just Met Its Match
A two-drug combo shrank tumors and extended survival in mice across four cancer types by exploiting a paradox in the BAP1 gene: in mesothelioma, germline BAP1 mutations are linked to high cancer susceptibility but less aggressive tumors. The combination (an LSD1 inhibitor plus AstraZeneca's Lynparza) overwhelms cancer cells' remaining DNA repair systems. Both drugs already have human safety data, potentially shortening the path to clinical trials.
Read more →